GGrantIndex
Sort

23,748 grants matching melanoma

Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122

$648,555
David A. Hafler · Yale University · R01 · FY2024 · CA

Peripheral immune surveillance and long-lived barrier immunity through T cell DC cross-talk

$648,534
Niroshana Anandasabapathy · Weill Medical Coll Of Cornell Univ · R56 · FY2021 · AR

IMAGING TELOMERE MAINTENANCE MECHANISMS IN GLIOMAS

$648,075
Pavithra Viswanath · University Of California, San Francisco · R01 · FY2021 · CA

Regulatory T cells in cancer therapy

$647,392
Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2025 · CA

Regulatory T cells in cancer therapy

$647,349
Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2021 · CA

Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistance

$647,072
Roger S Lo · University Of California Los Angeles · R01 · FY2025 · CA

Small-molecule degraders of STAT5

$646,994
Shaomeng Wang · University Of Michigan At Ann Arbor · R01 · FY2023 · CA

Small-molecule degraders of STAT5

$646,849
Shaomeng Wang · University Of Michigan At Ann Arbor · R01 · FY2025 · CA

Validating and Characterizing a New Melanoma Therapeutic Target

$646,803
Sara A Courtneidge · Oregon Health & Science University · R01 · FY2017 · CA

IN VIVO IMAGING OF SINGLE CIRCULATING CELLS

$646,722
Lihong Wang · Washington University · R01 · FY2015 · CA

Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments

$646,659
Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2022 · CA

Cancer Resistant Mice

$646,549
Bruce A Beutler · Ut Southwestern Medical Center · R01 · FY2024 · CA

IMMUNOTHERAPY OF MELANOMA: TARGETING HELIOS IN THE TUMOR MICROENVIRONMENT FOR EFFECTOR CELL CONVERSION

$646,313
Dana-Farber Cancer Institute, Inc. · · FY2017 · Department of the Army

Plasma-based therapies for bone infection: A tripartite USA/Northern Ireland/Republic of Ireland consortium

$646,298
Theresa A Freeman · Thomas Jefferson University · R01 · FY2024 · AR

Determining the clinical impact of gene expression testing in localized prostate cancer

$646,294
Todd M. Morgan · University Of Michigan At Ann Arbor · R01 · FY2022 · CA

Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients

$646,146
Robert H Vonderheide · University Of Pennsylvania · P01 · FY2021 · CA

Targeting RAS in Pediatric Cancer

$646,143
Marielle Yohe · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

Innate Immune Control of TB and HIV

$646,050
Anne Goldfeld · Boston Children'S Hospital · R56 · FY2021 · AI

A Multi-Level Investigation of US Indoor Tanning PolicyEnactment, Implementation, Compliance, Impact, and Economics

$645,949
Carolyn J. Heckman · Rbhs -Cancer Institute Of New Jersey · R01 · FY2021 · CA

The role of IWS1 in development and tumorigenesis

$645,852
Philip N Tsichlis · Ohio State University · R01 · FY2018 · CA

Designer extracellular vesicles for cancer therapy

$645,726
Xiaowei Xu · University Of Pennsylvania · R01 · FY2025 · CA

Retinoic Acid Induced Lymphangiogenesis for Post-Surgical Lymphedema

$645,721
Alex K. Wong · Rutgers Biomedical And Health Sciences · R01 · FY2024 · HL

An innovative, curriculum-based integrated sun exposure behavior intervention for

$645,278
Myles G Cockburn · University Of Southern California · R01 · FY2013 · CA

Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic Machinery

$645,228
Michael Davies · Wistar Institute · U54 · FY2017 · CA

Enhanced Development of the Xiphophorus Model System

$645,034
Yuan Lu · Texas State University · R24 · FY2019 · OD